VJOncology is committed to improving our service to you

ESMO 2019 | Updates on JAVELIN renal 101: primary treatment for patients

VJOncology is committed to improving our service to you

Laurence Albiges

Laurence Albiges, MD, PhD, Gustave Roussy Institute, Villejuif, France, discusses the updated results seen in the JAVELIN renal 101 study (NCT02684006), regarding the combination therapy of avelumab plus axitinib versus sunitinib as a first-line treatment of advanced renal cell carcinoma. Dr Albiges focuses primarily on the group of participants for whom this is primary treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter